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Abstract: We reported a 75-year-old diabetic man, who developed opacification and 
neovascularization of the posterior capsule after extracapsular cataract extraction and posterior 
chamber intraocular lens implantation. The patient was treated with two injections of 2.5 mg 
of intravitreal bevacizumab. The treatment produced an important regression of the posterior 
capsular new vessels, allowing us to perform a successful Nd:YAG capsulotomy, clearing the 
visual axis and improving the visualization of the posterior pole. Even though, best corrected 
visual acuity was 20/200 due to diabetic macular edema.
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Introduction
Cataract surgery in diabetic patients is associated with higher risk of postoperative 
complications. Posterior capsule opaciﬁ  cation (PCO), anterior capsule phimosis, 
severe inﬂ  ammation (ﬁ  brinous exudates and membrane), cystoid macular edema, and 
exacerbation of diabetic retinopathy are a few of the most important postoperative 
complications (Krupsky et al 1991; Chung et al 2002; Hayashi et al 2002; Hauser et al 
2004; Ivancic et al 2005; Ebihara et al 2006).
However the progression to a proliferative state is a common condition in these 
patients, ﬁ  nding new vessels behind the posterior capsule is a rare event. This particular 
ﬁ  nding is a hallmark of proliferative progression. The term, “rubeosis capsulare”, 
coined by Eifrig and colleagues (1990) is used to address this condition.
The role of the vascular endothelial growth factor (VEGF) in the pathogenesis 
of ischemic retinopathies is well known. It is a key factor in the development of 
retinal vascularization and its blockade has been related with rapid regressions of 
retina and iris new vessels secondary to proliferative diabetic retinopathy (Avery 
et al 2006).
Bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA, USA) is a full-
length humanized anti-VEGF monoclonal antibody, approved in the United States for 
the treatment of metastatic colorectal cancer. It has been used in ophthalmology as 
an off-label treatment of choroidal neovascularization, central retinal vein occlusion, 
and proliferative diabetic retinopathy, with encouraging preliminary results (Yang 
et al 2003; Bakri et al 2007).
We reported; a case of posterior capsule neovascularization in a diabetic patient 
who presented adequate regression of the new vessels with intravitreal bevaci-
zumab, allowing us to perform a successful Nd:YAG capsulotomy without serious 
complications.Clinical Ophthalmology 2008:2(3) 658
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Case report
A 75-year-old diabetic male was attended in our department 
with referral to slow progressive visual loss in both eyes since 
2 years prior. The visual loss was more signiﬁ  cant in the right 
eye. He had relevant medical history of long standing type 
2 diabetes mellitus, high blood pressure, and amputation of 
the left inferior limb due to a severe infection. The patient 
also had history of extracapsular cataract extraction with 
intraocular lens (IOL), implantation without complications 
three years before the ﬁ  rst symptom, and proliferative dia-
betic retinopathy treated with panretinal photocoagulation 
in both eyes.
In the physical examination, the patient had visual acu-
ity of count ﬁ  ngers in the right eye (OD) and 20/100 in the 
left eye (OS). There was a signiﬁ  cant PCO, with severe 
neovascularization in the OD at the slit – lamp examination 
(Figure 1). We offered the patient an off-label treatment with 
intravitreal bevacizumab in the right eye. The patient agreed 
and signed an informed consent form.
An intravitreal injection of 2.5 mg of bevacizumab was 
administered without complications. Five days after the treat-
ment, there was a notorious decrease in the posterior capsule 
neovascularization. One month after, the neovascularization 
continued, we chose to give a second dose of intravitreal 
bevacizumab to our patient.
Two weeks after the second dose, there was no appar-
ent neovascularization in the posterior capsule. We decided 
to perform a Nd:YAG capsulotomy. During the procedure, 
the patient had a small bleed (Figure 2), forming a clot that 
slowly disappeared 2 weeks after laser treatment.
The final best corrected visual acuity in OD was 
20/200 and 20/20 in OS with a clear visual axis (Figure 3). 
A persistent macular edema and active proliferative diabetic 
retinopathy was seen in the ﬂ  uorescein angiography.
Discussion
The incidence of PCO varies widely, depending on the 
cataract surgery technique, IOL material, edge design, his-
tory of intraocular inﬂ  ammation, patient age, the presence 
of pseudoexfoliation before surgery, among others. Never-
theless, diabetes mellitus has been known historically, as a 
deﬁ  nitive risk factor (Schaumberg et al 1998; Edihara et al 
2006). PCO in diabetic patients undoubtedly interferes with 
postoperative fundoscopy, retinal photocoagulation treat-
ment and vitrectomy, so it is important to maintain a clear 
visual axis.
The progression of diabetic retinopathy stages after cata-
ract surgery is a controversial issue. While some authors state 
that there is a deﬁ  nite progression, others state the opposite. 
They said that the progression seen after surgery is only the 
disease natural history (Murtha et al 2007).
The progression of diabetic retinopathy after cataract 
surgery includes the development of abnormal new vessels 
in the vitreous of untreated or insufﬁ  ciently treated patients, 
macular edema, neovascular glaucoma and rubeosis iridis 
(Ivancic et al 2005). In this particular case, the neovascu-
larization was so severe that reached and spread over the 
posterior capsule.
To our knowledge, there are only four reported cases in 
the literature of posterior capsule neovascularization after 
cataract surgery. Three of them had diabetic retinopathy. 
In the remaining case, the neovascularization was related 
to prior surgeries (pneumatic retinopexy and pars plana vit-
rectomy). The cases, until now reported, have been treated 
with vitrectomy and endophotocoagulation, intravitreal 
bevacizumab, and photodynamic therapy. There are no well 
deﬁ  ned treatments for this rare complication (Eifrig et al 
1990; Ayata et al 2007; Eren et al 2007).
The other reported case, in which the patient was also 
treated with intravitreal bevacizumab, the detection of the 
new vessels behind the posterior capsule was done only 
one year after the surgery. The intravitreal dose was 1.25 
mg and it required only one administration. One week 
after the treatment they performed a Nd:YAG capsulotomy 
with no complications. During the follow-up time of four 
weeks the patient did not present any complications (Eren 
et al 2007).
In our case, a single intravitreal injection of bevacizumab 
was not enough to induce an adequate regression of the 
posterior capsule neovascularization, so a second intravitreal 
injection was necessary to further decrease it and allow us to 
perform a Nd:YAG capsulotomy. During the procedure we 
had a small bleed, which slowly reduce until its complete 
disappearance, allowing a clear visual axis.
The follow-up time after the capsulotomy was two 
months. There were no complications in this time period. 
We consider that a longer follow-up time is needed to assure 
that there is no recurrence of new vessels in the remaining 
posterior capsule that can impair the visual acuity.
If the Nd:YAG capsulotomy would have been imple-
mented without prior administration of the intravitreal 
bevacizumab, the vessels behind the posterior capsule would 
have been patent at the moment of the laser treatment. In this 
particular scenario, the risk of a major vitreous hemorrhage 
with the subsequent loss of vision and even an increase of 
the IOP is very high.Clinical Ophthalmology 2008:2(3) 659
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Figure 1 Right slit-lamp images showing PCO with severe neovascularization and granules of pigment over the IOL. A) Direct illumination. B) Retroillumination with mydriasis.
A B
Figure 3 Two months after treatment slit-lamp images. It shows a complete resolution of the clot and a clear visual axis. A) Direct illumination. B) Retroillumination.
Figure 2 Slit-lamp image immediately after posterior capsulotomy.  A small hemorrhage (clot) is seen behind the IOL.Clinical Ophthalmology 2008:2(3) 660
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In summary, intravitreal bevacizumab was an effective 
and safe treatment that induces regression of posterior capsule 
neovascularization that allowed us to perform a Nd:YAG 
capsulotomy with minimal complications.
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